(2E,4E)-N-[2-[[(2R,3R,4R,5R,6S)-2-(1,2-Dihydroxyethyl)-4,5-dihydroxy-6-(7H-purin-6-ylamino)oxan-3-yl]amino]-2-oxoethyl]tetradeca-2,4-dienamide (BioDeep_00000180297)

   

human metabolite blood metabolite


代谢物信息卡片


(2E,4E)-N-[2-[[(2R,3R,4R,5R,6S)-2-(1,2-Dihydroxyethyl)-4,5-dihydroxy-6-(7H-purin-6-ylamino)oxan-3-yl]amino]-2-oxoethyl]tetradeca-2,4-dienamide

化学式: C28H43N7O7 (589.3224)
中文名称:
谱图信息: 最多检出来源 Homo sapiens(blood) 82.89%

分子结构信息

SMILES: CCCCCCCCCC=CC=CC(=O)NCC(=O)NC1C(O)C(O)C(NC2=NC=NC3=C2NC=N3)OC1C(O)CO
InChI: InChI=1S/C28H43N7O7/c1-2-3-4-5-6-7-8-9-10-11-12-13-19(38)29-14-20(39)34-21-23(40)24(41)28(42-25(21)18(37)15-36)35-27-22-26(31-16-30-22)32-17-33-27/h10-13,16-18,21,23-25,28,36-37,40-41H,2-9,14-15H2,1H3,(H,29,38)(H,34,39)(H2,30,31,32,33,35)

描述信息

同义名列表

5 个代谢物同义名

(2E,4E)-N-[2-[[(2R,3R,4R,5R,6S)-2-(1,2-Dihydroxyethyl)-4,5-dihydroxy-6-(7H-purin-6-ylamino)oxan-3-yl]amino]-2-oxoethyl]tetradeca-2,4-dienamide; N-({[2-(1,2-dihydroxyethyl)-4,5-dihydroxy-6-[(9H-purin-6-yl)amino]oxan-3-yl]-C-hydroxycarbonimidoyl}methyl)tetradeca-2,4-dienimidate; N-({[2-(1,2-dihydroxyethyl)-4,5-dihydroxy-6-[(7H-purin-6-yl)amino]oxan-3-yl]carbamoyl}methyl)tetradeca-2,4-dienamide; N-({[2-(1,2-dihydroxyethyl)-4,5-dihydroxy-6-(7H-purin-6-ylamino)oxan-3-yl]carbamoyl}methyl)tetradeca-2,4-dienamide; 6-(4-Deoxy-4-((2E,4E)-tetradecadienoylglycyl)amino-L-glycero-b-L-mannoheptopyranosyl)amino-9H-purine



数据库引用编号

3 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • Jeffrey G Supko, Joseph P Eder, David P Ryan, Michael V Seiden, Thomas J Lynch, Phillip C Amrein, Donald W Kufe, Jeffrey W Clark. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Nov; 9(14):5178-86. doi: . [PMID: 14613997]
  • Noboru Yamamoto, Tomohide Tamura, Yoshikazu Kamiya, Hiroyuki Ono, Hitoshi Kondoh, Kuniaki Shirao, Yasuhiro Matsumura, Yusuke Tanigawara, Yasuhiro Shimada. Phase I and pharmacokinetic study of KRN5500, a spicamycin derivative, for patients with advanced solid tumors. Japanese journal of clinical oncology. 2003 Jun; 33(6):302-8. doi: 10.1093/jjco/hyg051. [PMID: 12913085]
  • S M Gadgeel, R R Boinpally, L K Heilbrun, A Wozniak, V Jain, B Redman, M Zalupski, R Wiegand, R Parchment, P M LoRusso. A phase I clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a phase I accelerated titration "2B" design. Investigational new drugs. 2003 Feb; 21(1):63-74. doi: 10.1023/a:1022972427532. [PMID: 12795531]
  • H Takama, H Tanaka, T Sudo, T Tamura, Y Tanigawara. Population pharmacokinetic modeling and model validation of a spicamycin derivative, KRN5500, in phase 1 study. Cancer chemotherapy and pharmacology. 2001 May; 47(5):404-10. doi: 10.1007/s002800000257. [PMID: 11391855]
  • K Takara, Y Tanigawara, F Komada, K Nishiguchi, T Sakaeda, K Okumura. The novel anticancer drug KRN5500 interacts with, but is hardly transported by, human P-glycoprotein. Japanese journal of cancer research : Gann. 2000 Feb; 91(2):248-54. doi: 10.1111/j.1349-7006.2000.tb00938.x. [PMID: 10761713]
  • H Kawai. [Protein synthesis inhibitor--antitumor activity and mode of action of KRN 5500]. Gan to kagaku ryoho. Cancer & chemotherapy. 1997 Sep; 24(11):1571-7. doi: . [PMID: 9309156]
  • E Yoshioka, M Morino, H Tanaka, H Shinkai. Manual and automatic extraction and high-performance liquid chromatographic determination of a spicamycin derivative, KRN5500, in rat plasma. Journal of chromatography. B, Biomedical sciences and applications. 1997 Apr; 691(2):371-5. doi: 10.1016/s0378-4347(96)00430-6. [PMID: 9174273]
  • A M Burger, G Kaur, M Hollingshead, R T Fischer, K Nagashima, L Malspeis, K L Duncan, E A Sausville. Antiproliferative activity in vitro and in vivo of the spicamycin analogue KRN5500 with altered glycoprotein expression in vitro. Clinical cancer research : an official journal of the American Association for Cancer Research. 1997 Mar; 3(3):455-63. doi: . [PMID: 9815705]
  • M Kamishohara, H Kawai, T Sakai, T Uchida, T Tsuruo, N Otake. Inhibitory effect of a spicamycin derivative, KRN5500, on the growth of hepatic metastasis of human colon cancer-producing tissue polypeptide antigen. Cancer chemotherapy and pharmacology. 1996; 38(6):495-8. doi: 10.1007/s002800050517. [PMID: 8823489]